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Objective: Inhibitors of histone deacetylases are potent inducers of cell-cycle arrest
and apoptosis in certain malignancies. We have previously demonstrated that
chemotherapy activates the antiapoptotic transcription factor nuclear factor B in
non–small cell lung cancer and fails to induce significant levels of apoptosis. We
hypothesize that nuclear factor B inhibition with the proteasome inhibitor bort-
ezomib (formerly known as PS-341) will sensitize non–small cell lung cancer cells
to histone deacetylase inhibitor–mediated apoptosis.
Methods: Tumorigenic non–small cell lung cancer cells (A549, H358, and H460)
were treated with bortezomib, followed by the histone deactylase inhibitor sodium
butyrate. After treatment, nuclear factor B transcriptional activity was measured by
using a luciferase reporter assay and transcription of the nuclear factor B–
dependent gene IL8. Apoptosis was determined on the basis of caspase-3 activation
and DNA fragmentation. Western blot analyses for the cell-cycle regulatory proteins
p21 and p53 were performed, and cell-cycle alterations were determined by means
of FACS analysis. Experiments were performed in triplicate, and statistical signif-
icance was determined by using unpaired t tests.
Results: Butyrate increased nuclear factor B transcriptional activity 4-fold relative
to that seen in control cells (P  .05) in all non–small cell lung cancer cell lines.
Treatment with bortezomib reduced butyrate-induced activation of nuclear factor
B to baseline levels. The proteins p21 and p53 were stabilized after treatment with
bortezomib, correlating with a G2/M cell-cycle arrest. Treatment with butyrate alone
resulted in minimal apoptosis, but combined histone deacetylase and proteasome
inhibition increased apoptosis 3- to 4-fold (P  .02).
Conclusions: Combined molecular targeting of histone deacteylases and protea-
somes synergistically induced apoptosis in non–small cell lung cancer. Pharmaco-
logic nuclear factor B suppression through proteasome inhibition, followed by
treatment with histone deacetylase inhibitors, might represent a novel treatment
strategy for patients with non–small cell lung cancer.
There has been a significant lack of improvement in the long-termsurvival of patients given a diagnosis of non–small cell lung cancer(NSCLC) over the past 30 years. Initial enthusiasm for combinationthird-generation chemotherapeutic agents has been tempered by thework of the recent Eastern Cooperative Oncology Group trial1 andothers,2 which has shown that the benefits of chemotherapy for
locoregionally advanced or metastatic NSCLC are marginal (an increase in survival
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of 2-3 months) in good-performance-status patients. This
suggests that chemotherapy for advanced or recurrent
NSCLC has likely reached a plateau, with little differences
noted among various combinations of drugs.3 The lack of
improvement in overall survival and the failure of current
systemic therapies have mandated that new approaches to
this disease be explored.
Advances in the understanding of acetylation and
deacetylation of nucleosome core histones have prompted
investigators to evaluate the role of histone deacetylase
(HDAC) inhibitors as novel anticancer agents.4-7 HDACs
have been associated with several well-characterized tumor
suppressor genes (p53 and Rb) and the oncogene Myc.4 In
addition, gene silencing by HDAC complexes has been
shown to be an important mechanism in the development of
acute promyelocytic leukemia, acute myeloid leukemia, and
certain lymphomas.8,9 The inhibition of gene silencing by
HDACs has resulted in the evaluation of several structurally
dissimilar inhibitors of HDAC activity. HDAC inhibitors
have been shown to induce tumor cells to undergo cell-cycle
arrest,10,11 to upregulate p21 and p53 expression,10,12 to
inhibit angiogenesis,13 and to promote apoptosis.6,14 The
HDAC inhibitors phenylbutyrate, depsipeptide, and sub-
eroylanilide hydroxamic acid (SAHA) are all currently in
phase I or II clinical trials.5
In addition to exploring novel anticancer agents, such as
HDAC inhibitors, another approach to improving the treat-
ment of NSCLC is to identify and subsequently exploit the
tumor biology of NSCLC by evaluating cell-signaling path-
ways that modulate resistance to current therapies. More
than 80% of NSCLC tumor specimens overexpress subunits
of the nuclear factor (NF) B family relative to adjacent
normal lung tissue, suggesting that this antiapoptotic tran-
scription factor is dysregulated in NSCLC.15 Our laboratory
has previously reported that the transcription factor NF-B
is upregulated in NSCLC after treatment with chemotherapy
and that inhibition of NF-B with an adenovirally delivered
dominant-negative inhibitor of NF-B markedly sensitized
NSCLC cells to caspase-mediated apoptosis.16,17 Moreover,
we have also recently found that various HDAC inhibitors
activate NF-B–dependent transcription through Akt-medi-
ated phosphorylation of the coactivator protein p300.18
Thus inhibition of the antiapoptotic NF-B pathway com-
bined with a genotoxic stressor appears to be a plausible
treatment strategy for patients with NSCLC.
NF-B is normally sequestered in the cytoplasm by the
inhibitory protein IB. NF-B activation occurs by either
cytokines or intracellular stress signals that result in Akt,
IKK, or both kinase-mediated phosphorylation of IB. Spe-
cifically, phosphorylation of IB on serines 32 and 36 marks
IB for ubiquitination and degradation by the 26S protea-
some. IB degradation facilitates nuclear translocation of
the transcriptionally active NF-B isoform p50/p65, leading
to transcription of NF-B–dependent antiapoptotic genes.
Thus inhibition of proteasome-mediated degradation of IB
would prevent subsequent translocation of NF-B to the
nucleus and would be one approach to inhibit stimulus-
induced NF-B activation. There are several small-mole-
cule proteasome inhibitors currently undergoing evaluation,
including bortezomib (Velcade, formerly known as PS-
341)19 and MG-132.20 Although no phase I studies have
been performed with MG-132, phase I studies have been
completed with bortezomib, and they suggest that it is well
tolerated. In addition, it appears to have moderate efficacy
in treating multiple myeloma and chronic lymphocytic leu-
kemia.21,22
Therefore the purpose of this study was to determine
whether the small-molecule proteasome inhibitor bort-
ezomib would abrogate HDAC inhibitor–induced NF-B
activation in NSCLC and whether combined proteasome
and HDAC inhibition would sensitize NSCLC cells to un-
dergo apoptosis.
Methods
Cell Culture, Reagents, and Plasmid Constructs
Human NSCLC lines (NCI-H358, NCI-H460, and NCI-A549)
were grown in RPMI-1640 (Life Technologies, Inc, Carlsbad,
Calif) supplemented with 10% fetal bovine serum (Hyclone Lab-
oratories, Logan, Utah) and penicillin-streptomycin. These cell
lines were chosen because they comprise a representative panel of
clinical NSCLC on the basis of their varying expression levels of
p53, p16, and Rb proteins. The 3x-B luciferase reporter construct
contains NF-B DNA-binding consensus sites originally identified
in the MHC class I promoter fused upstream to firefly luciferase.
The Gal-4 luciferase construct contains 4 Gal-4 DNA consensus
binding sites derived from the yeast GAL-4 gene promoter cloned
upstream of luciferase cDNA. The Gal4-p65 fusion protein has the
yeast Gal-4 DNA-binding domain fused to full-length p65 (1-551)
and was previously described. Antibodies against p21 and p53
were obtained from Santa Cruz biotechnologies (Santa Cruz,
Calif). Sodium butyrate and MG-132 were purchased from Sigma-
Aldrich (St Louis, Mo), and bortezomib was kindly provided
through a materials transfer agreement with Millennium Pharma-
ceuticals (Cambridge, Mass).
Cell Viability Assay
NSCLC cells were treated with sodium butyrate at the appropriate
dose for 24 or 36 hours. Cell viability was determined by sequen-
tially incubating the cells in 1% glutaraldehyde, 0.5% crystal
violet, and distilled water at room temperature for 15 minutes each.
Cells were then thoroughly dried, and crystal violet dye was eluted
by incubating the cells in Sorenson’s solution (30 mmol/L sodium
citrate, 0.02 mol/L HCl, and 50% ethanol) at room temperature for
15 minutes. Optical density of the eluted dye was measured at a
wavelength of 570 nm.
HDAC Assays
NSCLC cells, plated in 100-mm dishes for 18 hours, were left
untreated or were cultured in the presence of sodium butyrate (500
mol/L). Eighteen hours after the addition of the HDAC inhibitor,
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cells were harvested, and nuclear extracts were isolated by using
previously described protocols.16 Nuclear protein samples were
quantified by using the Pierce BCA protein assay dye reagent
(Pierce, Rockford, Ill). Extracts (25 g) were analyzed for HDAC
activity by using the HDAC kit from Biomol (Plymouth Meeting,
Pa), as directed by the manufacturer.
Transfection and Luciferase Reporter Gene Assays
NSCLC cells at 60% to 80% confluency were transiently trans-
fected by using Polyfect reagent (Qiagen, Valencia, Calif) accord-
ing to the manufacturer’s instructions. Briefly, plasmid constructs
(0.75-1 g of DNA per well of a 12-well plate) were diluted in
serum-free media and mixed with the Polyfect reagent (4 L per
well). Complexes were allowed to form for 10 minutes before the
addition of complete media containing 10% fetal bovine serum.
The cells were washed once with 1 phosphate-buffered saline
(PBS), and Polyfect-DNA complexes were added to the cells and
placed in a humidified incubator at 37°C with 5% CO2. Six hours
after the start of transfection, additional complete media containing
the appropriate pharmacologic agent or agents for the experimental
conditions were added to the cells. Twenty-four hours after trans-
fection, cells were washed once with 1 PBS and lysed in lucif-
erase reporter buffer (Promega, Madison, Wis). Cells were then
snap-frozen and thawed in liquid nitrogen and a 37°C water bath,
respectively. Extracts were collected and cleared by means of
centrifugation at 14,000 rpm. Protein concentrations were deter-
mined with a Pierce BCA protein assay kit reagent (Peirce).
Luciferase assays were performed by using the substrate D-Lu-
ciferin (Promega), relative light units were measured with an
AutoLumat LB953 luminometer, and luminescence was normal-
ized to protein concentrations.
Western Blot Analysis
Logarithmically growing NSCLC cells were either left alone or
were treated with butyrate, bortezomib, or both for 12 hours. Cells
were harvested, and whole-cell lysates were prepared with RIPA
buffer (150 mmol/L NaCl, 25 mmol/L Tris, 5 nmol/L ethylenedi-
amine tetraacetic acid, 1% NP-40, and 0.5% deoxycholate). Cel-
lular proteins were quantified by using the Pierce BCA protein
assay kit. Proteins (50 g per well) were resolved on a 10%
polyacrylamide gel and then transferred to a nitrocellulose mem-
brane. Primary antibodies against p21 and p53 were used for
immunoblotting.
Northern Blot Analysis
Logarithmically growing NSCLC cells were either left alone or
were treated with sodium butyrate, bortezomib, or both for 12
hours. Total RNAs were isolated with Trizol reagent (Life Tech-
nologies Inc). RNAs (10 g per lane) were resolved on a dena-
turing 1.8% agarose-formaldehyde gel, transferred to Hybond
membrane (NEN/Perkin Elmer Life Sciences, Boston, Mass), and
cross-linked. Gene expression was determined by analyzing North-
ern blots with phosphorous 32 random-labeled probes generated
from IL8 or GAPDH cDNAs. After an 8-hour hybridization period,
the blots were washed twice in 2 standard saline citrate/0.1%
sodium dedecylsulfate for 15 minutes at room temperature and
twice in 0.1 standard saline citrate/0.1% sodium dedecylsulfate
for 15 minutes at 65°C. Northern blots were then analyzed by
means of autoradiography.
FACS Analysis
NSCLC cells were treated with the appropriate pharmacologic
agents for either 12 or 36 hours. Cells were then washed once with
1 PBS, followed by trypsinization and resuspension in ice-cold
70% ethanol for 24 hours or longer. Fixed cells were then incu-
bated for 12 hours in a propidium iodide staining solution (0.1%
Triton X-100, 0.2 mg/mL RNase, and 0.02 mg/mL propidium
iodide), and DNA content was determined the following day by
means of FACS analysis.
Apoptosis Assays
NSCLC cells were plated at 5  105 cells per well in a 12-well
plate. Twelve hours after plating, cells were either left alone or
treated with sodium butyrate, bortezomib, or both. After 30 hours
of treatment, cells were harvested, and apoptosis was quantified by
means of detection of caspase-3 activation and DNA fragmenta-
tion. Caspase-3 activity was determined by means of the addition
of an APC-DEVD protein conjugate (Calbiochem, San Diego,
Calif) to cellular lysates containing 25 g of protein. Fluorescence
of caspase-3–cleaved protein conjugates was determined fluoro-
metrically. DNA fragmentation was determined by means of eval-
uation of cellular nucleosome formation with the Cell Death De-
tection ELISA Plus kit (Roche, Indianapolis, Ind), according to the
manufacturer’s instructions.
Statistical Analysis
Statistical differences between treatment groups were determined
by using a 2-tailed unpaired Student t test when appropriate.
Results
HDAC Inhibitors Fail to Induce Apoptosis in NSCLC
Cells
HDAC enzymes reside within the nucleus, where they affect
numerous pathways involved with transcription, cell-cycle
regulation, differentiation, and apoptosis.4,6 Although it is
currently not understood how the disruption of HDAC ac-
tivity initiates apoptosis, HDAC inhibitors have been shown
to induce eukaryotic cell death in vitro and in vivo.4,6 H358,
H460, and A549 cells were treated with sodium butyrate at
doses ranging from 0 to 5000 mol/L to determine whether
the HDAC inhibitor sodium butyrate would induce apopto-
sis in NSCLC cell lines. Cell survival was determined by
using a crystal violet assay. All NSCLC cell lines treated
were resistant to sodium butyrate–induced death, even at the
suprapharmacologic dose of 5000 mol/L (Figure 1, A).
Cells were treated with butyrate, and nuclear extracts were
prepared as previously described to determine whether so-
dium butyrate effectively inhibited HDAC activity in the
NSCLC cell lines tested. Butyrate effectively inhibited 95%
or more of the HDAC activity in each NSCLC cell line
tested (Figure 1, B). These results suggest that the HDAC
inhibitor sodium butyrate is limited in its ability to induce
cell death in those NSCLC cell lines evaluated, despite
effectively inhibiting HDAC activity.
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Proteasome Inhibition Abrogates Sodium Butyrate–
Induced Activation of NF-B
The proteasome inhibitor bortezomib has been shown to
inhibit cytosolic degradation of phosphorylated IB,
thereby preserving its inhibitory effects on NF-B.23
NSCLC cell lines were transiently transfected with either
3x-B luciferase reporter constructs or cotransfected with a
Gal4 luciferase reporter construct and a full-length p65 Gal4
expression construct to determine whether proteasome in-
hibition would reduce either basal or sodium butyrate–
induced activation of NF-B. Sodium butyrate significantly
enhanced activation of NF-B, as determined by the 3x-B
reporter gene, and this activation was completely abrogated
by treatment with bortezomib (Figure 2, A). Similarly, bort-
ezomib repressed the transactivation potential of p65 in-
duced by sodium butyrate (Figure 2, B). Endogenous
NF-B activity was also determined by means of Northern
blot analysis with radiolabeled probes specific for the tightly
NF-B–regulated endogenous gene IL8. Butyrate enhanced
IL8 transcription, but this increased transcription of IL8 was
reduced to basal levels after treatment with butyrate com-
bined with bortezomib (Figure 2, C). Thus proteasome
inhibition with the small-molecule inhibitor bortezomib sig-
nificantly reduced activation of the transcription factor NF-
B.
Proteasome Inhibition Preserves Cell-Cycle Protein
Levels and Induces a G2/M Cell-Cycle Arrest
Previous reports have indicated that proteins involved in
cell-cycle regulation are degraded by cytosolic protea-
somes.19 Western blot analyses were performed on cells
treated for 12 hours with sodium butyrate, bortezomib, or
both to address the question of whether bortezomib would
affect cell-cycle regulatory proteins and induce subsequent
cell-cycle dysregulation in NSCLC. Sodium butyrate in-
duced no appreciable increases in p21 and p53 protein
levels. In contrast, bortezomib, alone or with butyrate, sta-
bilized levels of p53 and p21 (Figure 3, A). FACS analysis
was performed on each of the 3 cell lines with either sodium
butyrate, bortezomib, or both for 12 hours to determine
whether dysregulation of p21 or p53 levels correlated with
alterations in the cell cycle. The 12-hour treatment period
Figure 1. A, NSCLC cells were treated with butyrate (0-5000
mol/L) for 24 hours. Cell viability was determined on the basis
of crystal violet uptake. B, NSCLC cells were incubated in the
presence or absence of butyrate (500 mol/L), and nuclear HDAC
activity was determined.
Figure 2. A and B, NSCLC cells were transfected with either the
3x-B reporter gene or cotransfected with Gal4-p65 and the
Gal4-luciferase reporter gene and treated with nothing, butyrate,
bortezomib (bortz), or butyrate and bortezomib (*P  .04). C, A549
cells were similarly treated, and Northern blot analysis for IL8
was performed.
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was selected to allow time for cells to accumulate at a given
arrest point but to prevent DNA fragmentation caused by
apoptosis. Sodium butyrate alone did not appear to have a
significant effect on cell-cycle regulation, but treatment
with bortezomib was associated with a marked G2/M arrest
(Figure 3, B) in all cell lines.
Combined Proteasome and HDAC Inhibition Enhance
Cell Death Through Apoptosis
On the basis of data presented in Figure 3, further experi-
ments were conducted to determine whether inhibition of
NF-B transcription with bortezomib would sensitize
NSCLC cells to butyrate-induced cell death. NSCLC cells
Figure 3. A, H358, H460, and A549 cells were treated with nothing, bortezomib (bortz), bortezomib and butyrate, or
butyrate alone. Western blots were performed with antibodies for p21, p53, and -tubulin. B, NSCLC cells were
treated as noted above and analyzed by means of FACS analysis.
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were treated with nothing, butyrate, bortezomib, or both
butyrate and bortezomib, and cell death was determined by
means of the crystal violet assay. As shown in Figure 4,
there is a significant decrease in NSCLC cell survival after
combined proteasome and HDAC inhibition compared with
after any of the other treatments (P  .01). DNA fragmen-
tation and caspase-3 assays were performed to assess
whether this decrease in cell survival was caused by apo-
ptosis, as shown in Figure 5, A and B. Combined treatment
with butyrate and bortezomib significantly increased DNA
fragmentation relative to any of the other treatment groups
(P  .02; Figure 5, A). Similar results were seen with
caspase-3 activation after combined treatment with butyrate
and bortezomib relative to the other treatment groups (P 
0.03; Figure 5, B). Thus combined HDAC and proteasome
inhibition significantly increased DNA fragmentation and
caspase-3 activation, which is consistent with cellular death
occurring by means of apoptosis. FACS analysis was per-
formed on the H358 NSCLC cells to assess the degree of
apoptosis, and there was a 3- to 12-fold increase in apopto-
sis in the combined treatment group, as measured by the
percentage of cells in the subG0/G1 phase.
Discussion
Current treatment options for patients with locoregionally
advanced, metastatic, or recurrent NSCLC include chemo-
therapy, irradiation, palliative care, and, rarely, surgical
intervention. Unfortunately, in the majority of cases these
treatment strategies result in little improvement in survival,
although symptom relief and quality of life might be im-
proved. Thus there is an increasing effort to better under-
stand the biology of tumors, including their ability to grow
and metastasize, as well as what genes or signal transduc-
tion pathways regulate their resistance to conventional ther-
apies. Despite advances in understanding the biology of
certain tumors (ie, chronic myeloid leukemia) and the suc-
cessful clinical translation of those findings (ie, Gleevec,
Novartis Pharmaceuticals), similar success stories have re-
mained elusive for solid tumors, particularly lung cancer.
Histone acetylation-deacetylation controls gene tran-
scription and is regulated by 2 families of enzymes, histone
acetyltransferases and HDACs.4,5 Transcriptionally active
genes are typically associated with increased histone acet-
ylation, whereas low levels of acetylation correlate with
transcriptional repression.4 Inhibition of HDAC activity by
HDAC inhibitors has recently been shown to mediate tumor
cell growth arrest, enhance apoptosis, and promote cell-
cycle arrest.10-13,24 Encouraging in vitro and in vivo results
have led to several Phase I trials with the HDAC inhibitors
phenylbutyrate,25 SAHA,21 and depsipeptide.26 Although
toxicity profiles with these agents have been favorable, it is
unclear how effective these agents will be in affecting a
tumor response. Using 3 different NSCLC cell lines and the
HDAC inhibitor sodium butyrate, we were able to demon-
strate that despite completely inhibiting all intranuclear
deacetylase activity, all NSCLC cell lines evaluated were
resistant to HDAC inhibitor–mediated cell death (Figure 1,
B). These results have been confirmed with other HDAC
inhibitors, including trichostatin A (TSA) and SAHA.18
Figure 4. NSCLC cells were treated with nothing, butyrate, bortezomib (bortz), or combined butyrate and bort-
ezomib. Cell survival was determined by means of crystal violet assay (*P  .01, †P  .06).
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On the basis of previous work by our group,16-18,23 we
next sought to identify whether HDAC inhibition activated
the antiapoptotic transcription factor NF-B. Recent studies
have suggested that acetylation of specific lysine residues
on the RelA/p65 subunit of NF-B controls DNA binding
and facilitates IB-mediated nuclear exportation of NF-B,
thus regulating NF-B–dependent transcription.27 As
shown in Figure 2, butyrate increased NF-B–dependent
transcription, and this effect was ameliorated after treatment
with the proteasome inhibitor. The exact mechanism by
which HDAC inhibitors activate NF-B is unclear, although
we have recently shown that it likely involves phosphory-
lation of the coactivator protein p300 by the serine-threo-
nine kinase Akt.18
The 26S proteasome is the primary component of the
protein degradation pathway of the cell, and its rapid and
irreversible elimination of targeted proteins can activate or
repress many cellular processes, including cell-cycle pro-
gression and apoptosis.19 We have previously shown that
chemotherapy can activate NF-B by initiating phosphory-
lation of a cascade of cytosolic kinases culminating in the
phosphorylation of IB, thus marking it for ubiquitination
and subsequent degradation by the 26S proteasome.23
Therefore proteasome inhibition permits cytosolic seques-
Figure 5. A, NSCLC cells were treated with nothing, sodium butyrate, bortezomib (bortz), or butyrate and
bortezomib. Apoptosis was assessed and quantified by means of DNA fragmentation (A, *P  .02), caspase-3
activation (B, *P  .03), and flow cytometry (C).
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tration of NF-B by stabilizing IB and ameliorating all
NF-B–dependent transcription. Several studies have
shown that proteasome inhibition has antitumor activity
both alone and combined with chemotherapy, radiation, or
both.19 This encouraging antitumor activity has been shown
to be the result of inhibition of NF-B, as well as cell-cycle
arrest. The only proteasome inhibitor to enter clinical trial is
bortezomib.19,21 Phase I trials with bortezomib have been
completed and show that it is well tolerated.21 On the basis
of these results and our desire to identify a small-molecule
inhibitor of NF-B, experiments were performed to deter-
mine whether bortezomib would inhibit butyrate-induced
NF-B activation. As shown in Figure 2, in all NSCLC cell
lines evaluated, treatment with bortezomib significantly in-
hibited butyrate-induced NF-B–dependent transcription.
In addition to inhibiting NF-B activation, bortezomib
also has been shown to stabilize the cell cycle proteins p53,
p21, and p27.19 Similarly, HDAC inhibitors have been
shown to stabilize p21, downregulate cyclins A and D,
hypophosphorylate the tumor suppressor Rb, and induce
both G1 and S-phase cell-cycle arrest.3,4,12,24 Data shown in
Figure 4 indicate that the HDAC inhibitor butyrate partially
stabilized p21 in one cell line but not others and that
bortezomib alone and bortezomib-butyrate stabilized both
p21 and p53 protein levels. Other series have shown stabi-
lization of p21 with HDAC inhibition alone,12,24 but we did
not observe as robust of an increase as expected. This might
relate the specific HDAC inhibitor or cell type used for
experimentation. Importantly, combined HDAC and protea-
some inhibition did demonstrate a significant G2/M cell-
cycle arrest by means of FACS analysis (Figure 4, B), which
correlates with a previous report by Ling and colleagues.28
Thus combined HDAC and proteasome inhibition stabilized
p21 and p53 levels and induced a G2/M phase arrest in our
NSCLC cells.
In addition to demonstrating that combined HDAC and
proteasome inhibition facilitates cell-cycle arrest, we also
demonstrated that this combined treatment markedly en-
hanced NSCLC cell death. This cell death was caused, in
part, by apoptosis, as measured by means of DNA fragmen-
tation, caspase-3 activation, and FACS analysis. There was
also a significant cell-cycle arrest after combined treatment,
as noted in Figure 3. The observation of enhanced apoptosis
in the setting of a cell-cycle arrest indicates that HDAC
inhibitor–mediated apoptosis might not depend on cell-
cycle progression, as is generally true for traditional che-
motherapeutic agents. Although the exact mechanism of
HDAC inhibitor–mediated apoptosis is not known, previous
reports have found treatment with HDAC inhibitors to result
in increased mitochondrial cytochrome c release, cleavage
of the proapoptotic Bcl-2 family member BID, and gener-
ation of reactive oxygen species.14 We and others have also
found that HDAC inhibitor–induced apoptosis can occur
independent of a death receptor pathway or the expression
of functional p53.14,18 Finally, we have also shown that
treatment with bortezomib and SAHA generates significant
reactive oxygen species that are proapoptotic in NSCLC
cells.
Limitations of this experimental approach include the
fact that only one HDAC and proteasome inhibitor were
evaluated. However, we have observed nearly identical re-
sults with other HDAC inhibitors (TSA and SAHA) and the
proteasome inhibitor MG-132. We chose to evaluate bu-
tyrate and bortezomib because both have been through
Phase I clinical trials and because they have been the focus
of other experiments in the laboratory. Another potential
criticism of the study is that our findings are limited to our
NSCLC cell-culture model system. In vivo experiments
with NSCLC xenografts treated with combined HDAC and
proteasome inhibitors are currently ongoing in the labora-
tory. Finally, we only used one dose of sodium butyrate, and
there might have been further enhancement of apoptosis if a
dose-response curve had been generated. We chose the dose
of butyrate used in our experiments to be equivalent to the
biologic active concentration of 0.5 mmol/L identified in the
Phase I trial of butyrate in patients with refractory solid
tumor malignancies.25
To our knowledge, this is the first study to evaluate
combined proteasome and HDAC inhibition in NSCLC, as
well as in any other malignancy. In a disease in which
meaningful treatment options have remained frustratingly
few, pharmacomolecular treatment strategies are likely to
hold promise for the future. The genesis of this line of
investigation is based on our increasing understanding of
the important role that NF-B cell-signaling cascades play
in modulating resistance to both traditional and novel anti-
cancer therapies. This preliminary report strongly suggests
that combined proteasome and HDAC inhibition merits
further investigation as a treatment strategy for patients with
NSCLC and potentially other solid tumor malignancies.
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Discussion
Dr D. Nguyen (Bethesda, Md). Have you tested all the HDAC
inhibitors like SAHA or TSA?
Dr Denlinger. Yes, we performed similar experiments with
several HDAC inhibitors, including TSA and SAHA, and have
observed very similar results with each of these compounds.
Dr Nguyen. Can you offer some thought about mechanisms
why these drugs induce NF-B activation?
Dr Denlinger. Traditional chemotherapeutic agents activate
NF-B by inducing nuclear translocation of the transcriptionally
active p50/p65 heterodimer. In contrast, HDAC inhibitors appear
to enhance NF-B–dependent gene transcription without inducing
nuclear translocation. HDAC inhibitors activate NF-B by recruit-
ing transcriptional coactivators to NF-B–dependent promoters.
For example, we have recently demonstrated that the HDAC
inhibitor butyrate facilitates recruitment of the transcriptional co-
activator protein p300 to the IL-8 promoter. This correlates with
enhanced transcription of the NF-B–dependent gene IL8. There-
fore we believe that the HDAC inhibitors activate NF-B by
enhancing the transcriptional activity of p50/p65 heterodimers
present in the nucleus at baseline.
Dr Nguyen. You show in the Western blot about the p21
upregulation, and you show only one cell line. In the 460s, as I
could see, there is not much increase in p21 at all. In my experi-
ence I have looked at different HDAC inhibitors, and it is uni-
formly increased in all lung cancer–associated mesothelioma, and
usually upregulated p21 is a very good surrogate marker of HDAC
activities in the cells. Have you tried other blots or an enzyme-
linked immunosorbent assay to pick up p21 upregulation in the 460s?
Dr Denlinger. Could you rephrase that?
Dr Nguyen. Did you reblot the 460s with other HDAC inhib-
itors to see whether p21 also was upregulated?
Dr Denlinger. We also treated the H460 cell line with TSA and
did not observe significant upregulation of p21, despite the fact
that HDAC inhibitors have been shown to upregulate p21 in most
NSCLC cell lines.
Dr Nguyen. The last thing I want to check with you is whether
you have tried to block NF-B directly instead of using a protea-
some inhibitor? As you know, a proteasome inhibitor would do a
lot of other things in addition to blocking NF-B. Have you tried
using other agents? There are pharmacologic agents that are very
good at blocking binding of active NF-B through the DNA
consensus sequence of the DNA-binding site of NF-B. Have you
tried that yet?
Dr Denlinger. We have also combined HDAC inhibition with
direct inhibition of NF-B by using a mutant IB that is incapable
of phosphorylation and degradation. This IB mutant protein binds
NF-B in the cytoplasm and likely depletes the nuclear NF-B
population. We have shown that the mutant IB blocks HDAC
inhibitor–induced activation of NF-B and sensitizes NSCLC to
HDAC inhibitor–induced apoptosis. Importantly, this IB mutant
functions at essentially the same level as the proteasome inhibitor
bortezomib. Whereas the IB mutant cannot be phosphorylated at
serines 32 and 36, which marks IB for degradation by the 26S
proteasomes, bortezomib prevents degradation of endogenous IB
despite its phosphorylation at serines 32 and 36. We prefer to
experiment with the pharmacologic inhibitor of NF-B because it
is likely to have greater potential for clinical application.
General Thoracic Surgery Denlinger et al
1086 The Journal of Thoracic and Cardiovascular Surgery ● April 2004
G
TS
